Characteristics of selected studies for the prognostic value of mitral regurgitation in patients undergoing TAVI
| Author, country, year, ref | Design | Prospective | Universal | Consecutive recruitment | No. centres | Valve type | Inclusion period | n | Follow-up | % patients lost to follow-up | Independent adjudication event committee |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rodes-Cabau, Canada, 201016 | National Registry | Yes | Yes* | Yes | 6 | BEV | January 2005 to June 2009 | 339 | 240 days | 0 | No |
| Leon, USA, 20105 | RCT | Yes | Yes | No | 25 | BEV | May 2007 to March 2009 | 171 | 1.6 years | 0 | Yes |
| Smith, USA, 20116 | RCT | Yes | Yes | No | 25 | BEV | May 2007 to August 2009 | 334 | 1.4 years | 0.6 | Yes |
| Gilard, France, 201217 | National Registry | Yes | Yes | Yes | 34 | BEV/SEV | January 2010 to October 2011 | 3195 | 114 days | 0.2 | Yes |
| Zahn, Germany, 201318 | National Registry | Yes | No | Yes | 22 | BEV/SEV | January 2009 to June 2010 | 1391 | 12.9 months | 5.2 | No |
| D'Onofrio, Italy, 201319 | National Registry | Yes | No | Yes | 21 | BEV | April 2008 to June 2012 | 774 | 12 months | 0 | No |
| Bedogni, Italy, 20139 | National Registry | Yes | Yes† | Yes | 14 | SEV | June 2007 to April 2011 | 1007 | >1 year (97.3%) | 0 | Yes |
| Sabaté, Spain, 201320 | National Registry | No | No | No | 37 | BEV/SEV | January 2010 to December 2011 | 883 | 244 days | 3.7 | No |
*For Edwards valve.
†For initial Corevalve System experience.
BEV, balloon-expandable valve; RCT, randomised clinical trial; SEV, self-expandable valve.